![IDnow acquires Wirecard Communication Services](https://www.seventure.fr/wp-content/uploads/2022/10/systeme-protection-numerique-securite-con-322x211.jpg)
All
![Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field
Seventure Partners, a European leader in financing innovation, announces today that the technical committee of the French government initiative, which was set up to support...
![Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...
![Clim8 raises €2.75m Series A funding](https://www.seventure.fr/wp-content/uploads/2019/07/nos_fonds_instits_sport_performance-322x211.png)
Clim8 raises €2.75m Series A funding
The French company, founded in 2016, is a leader in the connected textiles market with its intelligent and patented thermal technologies. With more than 50% of its sales...
![Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates](https://www.seventure.fr/wp-content/uploads/2019/02/4__104270789-322x211.jpg)
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...
![Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps](https://www.seventure.fr/wp-content/uploads/2019/02/4__104270789-322x211.jpg)
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration...
![CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS](https://www.seventure.fr/wp-content/uploads/2019/02/4__104270789-322x211.jpg)
CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS
(BOSTON) – CARB-X announced today that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05...
![Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline](https://www.seventure.fr/wp-content/uploads/2019/02/4__104270789-322x211.jpg)
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...